Primary central nervous system lymphoma
Conditions
Interventions
experimental group:Pomadomide combined with rituximab, methotrexate, dexamethasone regimen
Sponsors
Chongqing University Affiliated Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18-70 years old, male or female, expected survival time: 3 months or more 2. Patients with primary central nervous system lymphoma diagnosed as CD20 positive by pathology without prior treatment 3. Signed an informed consent form before performing any specific operation 4. The patient has sufficient organ function, including: blood routine: ANC>=1 × 10 ^ 9/L, Hb>=80g/L, PLT>=75 × 109/L; Liver function results (total bilirubin40ml/min 5. At least one measurable lesion; 6. Researchers determine that patients with an expected life expectancy of at least 3 months
Exclusion criteria
Exclusion criteria: 1. If there is an allergic reaction to pomalidomide capsules or any excipients 2. Merge other uncontrolled malignant tumors 3. Severe heart failure (NYHA grade 3-4) 4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases 5. Adopt other anti-tumor treatments outside of this research protocol 6. Pregnant or lactating women 7. There are clinical situations where other researchers consider it inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate in the induced remission phase;Total response rate during induced remission phase; | — |
Countries
China
Contacts
Public ContactYao Liu
chongqing university cancer hospital
Outcome results
None listed